Kurma Partners

Kiro is an IT company that offers artificial intelligence, ergonomic design, and software development solutions for medical biology.

Ganymed Robotics SAS, a medical device company, focuses on the development of robotics technologies for orthopedic surgeons. It develops a therapeutic device to enhance surgical precision in knee replacement surgery. The company was incorporated in 2018 and is based in Paris, France.

Charles helps men regain control over their daily health concerns by starting with their personal health. The company was founded in Paris, Ile-de-France, France in 2019.

Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation. Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company is based in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.

ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.

DAMAE Medical SAS, founded in 2014 and based in Paris, France, specializes in developing advanced medical imaging technologies for dermatology. The company's flagship product, OCTAV, employs innovative optical imaging techniques to provide in vivo, cellular-level images of skin tissues, offering insights similar to traditional histology without requiring tissue excision or processing. This non-invasive approach enables dermatologists to assess the malignancy of skin tumors with precision and efficiency through simple contact with the skin's surface. By leveraging bio-photonics, DAMAE Medical aims to enhance diagnostic capabilities in dermatology, facilitating timely and accurate evaluations of skin cancer.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly those experiencing worsening and acute decompensated heart failure. The company focuses on addressing unmet medical needs in this area and aims to provide effective treatments that enhance understanding of the underlying disease biology. Additionally, Corteria's research extends to related conditions such as sarcopenia and obesity, positioning the company to make a significant impact on the management of these interconnected health issues.

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.

Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.

SmartCatch brings value-added liquid biopsy technology to empower clinicians, researchers, and industry in the fight against cancer.

Arkhn is a platform specialist in healthcare data interoperability. Arkhn tackles the issue of accessing healthcare data.

Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.

Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.

Lucine is focused on transforming patient health, primarily in the area of pain management. The company has developed a mobile health application that measures, analyzes, and alleviates pain from the comfort of home. Utilizing advanced algorithms, the application identifies the nature of a patient's pain by analyzing facial expressions, vocal cues, and posture. Based on this real-time assessment, it personalizes treatment options, offering techniques such as exercises, relaxation methods, art therapy, and meditation. The application aims to provide relief within five minutes through innovative analgesic neurostimulation, empowering patients with chronic pain to manage their symptoms effectively.

Corlieve Therapeutics SAS, a biotechnology company, develops therapeutic options to patients with severe neurological disorders. Its lead project is targeting aberrantly expressed kainate receptors in the hippocampus of patients with temporal lobe epilepsy (TLE) using a gene therapy approach. The company’s program employs a novel AAV gene therapy approach for the treatment of refractory TLE and is based on science from INSERM, CNRS, Aix Marseille University, and the University of Bordeaux. The company was incorporated in 2019 and is based in Paris, France.

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

Sensome SAS is a French company that specializes in the development and manufacturing of innovative medical micro-sensors aimed at enhancing invasive vascular medical devices. Founded in 2014 and headquartered in Massy, France, Sensome's technology utilizes AI-driven micro-sensors to provide real-time, non-invasive identification of tissue composition during medical procedures, particularly in stroke treatment. This breakthrough remote monitoring technology addresses the limitations of traditional vascular imaging techniques, facilitating better interventions and patient follow-ups. The company's proprietary sensor technology, which combines impedance-based micro-sensors with machine learning algorithms, offers high predictive reliability for identifying biological tissues. Sensome is focused on developing vascular access devices equipped with this technology, with plans to extend its applications to various medical fields, including neurovascular, peripheral vascular, and cardiovascular interventions.

Cardiologs Technologies SAS is a medical technology company based in Paris, France, that specializes in electrocardiogram (ECG) analysis to enhance cardiac patient management. Founded in 2014, the company offers the Cardiologs ECG Analysis Platform, a cloud-based service designed to assist physicians in screening for atrial fibrillation and other arrhythmias through long-term ambulatory ECG monitoring. Utilizing a proprietary database of over 1.4 million recordings and advanced deep learning technology, Cardiologs' solution is backed by clinical publications demonstrating its diagnostic effectiveness. The platform enables cardiologists to identify patterns in digital ECG signals from various compatible cardiac monitoring devices, ultimately aiming to make expert cardiac diagnostics more scalable and accessible within the healthcare sector.

ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.

FeetMe SAS, based in Paris, France, specializes in developing advanced insoles designed to monitor foot pressure in real time, particularly for diabetic patients. Founded in 2013, the company utilizes embedded pressure sensors in its insoles to create detailed pressure maps, enabling both patients and healthcare providers to detect changes in plantar pressure. This innovative technology addresses the significant global issue of mobility disorders, affecting approximately 100 million individuals. FeetMe's primary product, the FeetMe Monitor, combines connected insoles with mobile software to assess gait parameters and variability in real-life situations through smart algorithms and wireless connectivity. The company's solutions are marketed to pharmaceutical firms for clinical trials, rehabilitation centers for mobility assessments, and directly to patients for home rehabilitation, aiming to enhance therapeutic and rehabilitation evaluations.

Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation. Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company is based in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in Éragny-sur-Oise, France.

Sensome SAS is a French company that specializes in the development and manufacturing of innovative medical micro-sensors aimed at enhancing invasive vascular medical devices. Founded in 2014 and headquartered in Massy, France, Sensome's technology utilizes AI-driven micro-sensors to provide real-time, non-invasive identification of tissue composition during medical procedures, particularly in stroke treatment. This breakthrough remote monitoring technology addresses the limitations of traditional vascular imaging techniques, facilitating better interventions and patient follow-ups. The company's proprietary sensor technology, which combines impedance-based micro-sensors with machine learning algorithms, offers high predictive reliability for identifying biological tissues. Sensome is focused on developing vascular access devices equipped with this technology, with plans to extend its applications to various medical fields, including neurovascular, peripheral vascular, and cardiovascular interventions.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.

Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.

Cardiologs Technologies SAS is a medical technology company based in Paris, France, that specializes in electrocardiogram (ECG) analysis to enhance cardiac patient management. Founded in 2014, the company offers the Cardiologs ECG Analysis Platform, a cloud-based service designed to assist physicians in screening for atrial fibrillation and other arrhythmias through long-term ambulatory ECG monitoring. Utilizing a proprietary database of over 1.4 million recordings and advanced deep learning technology, Cardiologs' solution is backed by clinical publications demonstrating its diagnostic effectiveness. The platform enables cardiologists to identify patterns in digital ECG signals from various compatible cardiac monitoring devices, ultimately aiming to make expert cardiac diagnostics more scalable and accessible within the healthcare sector.

FeetMe SAS, based in Paris, France, specializes in developing advanced insoles designed to monitor foot pressure in real time, particularly for diabetic patients. Founded in 2013, the company utilizes embedded pressure sensors in its insoles to create detailed pressure maps, enabling both patients and healthcare providers to detect changes in plantar pressure. This innovative technology addresses the significant global issue of mobility disorders, affecting approximately 100 million individuals. FeetMe's primary product, the FeetMe Monitor, combines connected insoles with mobile software to assess gait parameters and variability in real-life situations through smart algorithms and wireless connectivity. The company's solutions are marketed to pharmaceutical firms for clinical trials, rehabilitation centers for mobility assessments, and directly to patients for home rehabilitation, aiming to enhance therapeutic and rehabilitation evaluations.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Sensome SAS is a French company that specializes in the development and manufacturing of innovative medical micro-sensors aimed at enhancing invasive vascular medical devices. Founded in 2014 and headquartered in Massy, France, Sensome's technology utilizes AI-driven micro-sensors to provide real-time, non-invasive identification of tissue composition during medical procedures, particularly in stroke treatment. This breakthrough remote monitoring technology addresses the limitations of traditional vascular imaging techniques, facilitating better interventions and patient follow-ups. The company's proprietary sensor technology, which combines impedance-based micro-sensors with machine learning algorithms, offers high predictive reliability for identifying biological tissues. Sensome is focused on developing vascular access devices equipped with this technology, with plans to extend its applications to various medical fields, including neurovascular, peripheral vascular, and cardiovascular interventions.

Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in Éragny-sur-Oise, France.

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.

ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.

DAMAE Medical SAS, founded in 2014 and based in Paris, France, specializes in developing advanced medical imaging technologies for dermatology. The company's flagship product, OCTAV, employs innovative optical imaging techniques to provide in vivo, cellular-level images of skin tissues, offering insights similar to traditional histology without requiring tissue excision or processing. This non-invasive approach enables dermatologists to assess the malignancy of skin tumors with precision and efficiency through simple contact with the skin's surface. By leveraging bio-photonics, DAMAE Medical aims to enhance diagnostic capabilities in dermatology, facilitating timely and accurate evaluations of skin cancer.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon (France), that develops, manufactures and markets innovative patient monitoring systems. The core focus of APD is to provide relevant indicators pertaining to tissue perfusion to clinicians. The recent market introduction of IKORUS® monitoring system addresses a unmet need up to now, and opens new fields of investigation for physicians, enabling early detection of microcirculatory alterations and potential improvement of current therapeutic practices.

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon (France), that develops, manufactures and markets innovative patient monitoring systems. The core focus of APD is to provide relevant indicators pertaining to tissue perfusion to clinicians. The recent market introduction of IKORUS® monitoring system addresses a unmet need up to now, and opens new fields of investigation for physicians, enabling early detection of microcirculatory alterations and potential improvement of current therapeutic practices.

BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

BliNK Biomedical SAS specializes in the discovery and development of first or best-in-class antibody-based therapeutics for life threatening diseases such as cancer with a focus on immuno-oncology disease targets. Our lead program is a monoclonal antibody that targets an immune checkpoint to cause an immune switch that renders tumors susceptible to the body's immune system. Our other programs address a number of attractive, novel immuno-oncology and immune-checkpoint targets, some of which are unique to our approach. The antibodies that we are developing have the potential to be the next generation of anti-tumor therapeutics.

Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in Éragny-sur-Oise, France.

ABM Pharma is a partner of the entire pharmacy network in the home care of patients, today more than 5000 pharmacies are clients. ABM Pharma technicians work with more than 30,000 patients.

PathoQuest SAS, a biotechnology company, offers a game changing metagenomics approach to improving the breadth of pathogen detection. The company offers products, such as (NGS) based testing approach delivers actionable reports to clinicians, biologists, and biopharmaceutical quality assurance managers and production managers. It provides iDTECTTM Dx Blood test, an approach to the identification of pathogens and iDTECTTM database and software suite that enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. The company also offers Viral Safety testing service for biopharmaceutical companies. It has strategic alliance with Charles River Laboratories International, Inc. PathoQuest SAS was founded in 2010 and is based in Paris, France.

Meiogenix SAS operates as a biotech company that develops breeding and genomic technologies. It offers SpiX technology, which modulates the process of homologous recombination in the genome by increasing its frequency in cold regions and PhoeniX, which is a non-GM method that induces meiotic recombination in hybrid diploid (or polyploid) yeast cells without the need to go through the entire process of meiosis. The company helps to develop new products to address global food and industrial challenges. The company was incorporated in 2010 and is based in Paris, France.

Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in Éragny-sur-Oise, France.